Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Neurology and Neuroscience Reports
Published in: Current Neurology and Neuroscience Reports 1/2010

01-01-2010 | Clinical Trial Report

Tonabersat: A Cortical Spreading Depression Inhibitor as Potential Pharmacologic Prophylaxis in Migraine with Aura

Author: Ivan Garza

Published in: Current Neurology and Neuroscience Reports | Issue 1/2010

Login to get access

Excerpt

Hauge AW, Asghar MS, Schytz HW, et al.: Effects of tonabersat on migraine with aura: a randomised, double-blind, placebo-controlled crossover study. Lancet Neurol 2009, 8(8):693–695. …
Literature
1.
Ayata C: Spreading depression: from serendipity to targeted therapy in migraine prophylaxis. Cephalalgia 2009, 29(10):1095–1114.CrossRefPubMed
2.
Tvedskov JF, Iversen HK, Olesen J: A double-blind study of SB-220453 (Tonerbasat) in the glyceryltrinitrate (GTN) model of migraine. Cephalalgia 2004, 24(10):875–882.CrossRefPubMed
3.
Ayata C, Jin H, Kudo C, et al.: Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol 2006, 59(4):652–661.CrossRefPubMed
4.
Goadsby PJ, Ferrari MD, Csanyi A, et al.: Randomized, double-blind, placebo-controlled, proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis. Cephalalgia 2009, 29(7):742–750.CrossRefPubMed
5.
Headache Classification Subcommittee of the International Headache Society: The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004, 24(Suppl 1):9–160.
6.
Bigal ME, Lipton RB: The epidemiology, burden, and comorbidities of migraine. Neurol Clin 2009, 27(2):321–334.CrossRefPubMed
7.
Kruit M, van Buchem M, Launer L, et al.: Migraine is associated with an increased risk of deep white matter lesions, subclinical posterior circulation infarcts and brain iron accumulation: the population-based MRI CAMERA study. Cephalalgia 2009 Jun 8 (Epub ahead of print).
8.
Scher AI, Gudmundsson LS, Sigurdsson S, et al.: Migraine headache in middle age and late-life brain infarcts. JAMA 2009, 301(24):2563–2570.CrossRefPubMed
Metadata
Title
Tonabersat: A Cortical Spreading Depression Inhibitor as Potential Pharmacologic Prophylaxis in Migraine with Aura
Author
Ivan Garza
Publication date
01-01-2010
Publisher
Current Science Inc.
Published in
Current Neurology and Neuroscience Reports / Issue 1/2010
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-009-0083-9

Other articles of this Issue 1/2010

Current Neurology and Neuroscience Reports 1/2010 Go to the issue

OriginalPaper

Evolution of the Thrombolytic Treatment Window for Acute Ischemic Stroke

OriginalPaper

Prevention of Stroke in Patients with High-Risk Atrial Fibrillation

OriginalPaper

Utility of Functional MRI in Pediatric Neurology

Clinical Trial Report

Ticagrelor, a New Antiplatelet Agent, for Prevention of Ischemic Events in Patients with Coronary Artery Disease

OriginalPaper

Seizures and Epilepsy in Cancer Patients

OriginalPaper

Neural Injury in Sleep Apnea